==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb


Details of Th1035 which contains 5 entries.


Entry 1
(1) Primary information
ID1252
ThPP IDTh1035
Therapeutic Peptide/Protein NameGlucagon recombinant
SequenceHSQGTFTSDYSKYLDSRRAQDFVQWLMNT view full sequnce in fasta
Functional ClassificationIV
Molecular Weight3767.1
Chemical FormulaC165H249N49O51S1
Isoelectric Point9.52
Hydrophobicity-1.197
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionGlucagon is a 29 residue peptide hormone, synthesized in a special non- pathogenic laboratory strain of Escherichia coli bacteria that has been genetically altered by the addition of the gene for glucagons.
Indication/DiseaseUsed to treat severe hypoglycemia, also used in gastrointestinal imaging.
PharmacodynamicsUsed in the treatment of hypoglycemia and in gastric imaging, glucagon increases blood glucose concentration and is used in the treatment of hypoglycemia. Glucagon acts only on liver glycogen, converting it to glucose through the release of insulin. It also relaxes the smooth muscles of the gastrointestinal tract.
Mechanism of ActionGlucagon binds the glucagon receptor(G protein-coupled receptor located in the plasma membrane) which then initiates a dual signaling pathway using both adenylate cyclase activation and increased intracellular calcium. Adenylate cyclase manufactures cAMP (cyclic AMP), which activates protein kinase A (cAMP-dependent protein kinase). This enzyme, in turn, activates phosphorylase kinase, which, in turn, phosphorylates glycogen phosphorylase, converting into the active form called phosphorylase A. Phosphorylase A is the enzyme responsible for the release of glucose-1-phosphate from glycogen polymers. This yields glucose molecules to be released into the blood. Glucagon receptors are found in the liver, kidney, brain and pancreatic islet cells. The glucagon mediated signals lead to an increase in insulin excretion
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of Distribution0.25 L/kg
Clearance13.5  mL/min/kg [Adults with IV 1 mg]
CategoriesHypoglycemic Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetGlucagon receptor,Glucagon-like peptide 2 receptor,Glucagon-like peptide 1 receptor
Information of corresponding available drug in the market
Brand NameGlucaGen
CompanyNovo Nordisk
Brand DiscriptionGlucaGen(29 amino acid residues, 3483 daltons, single polypeptide) is an antihypoglycemic agent and a gastrointestinal motility inhibitor. It is produced by expression of recombinant DNA in a Saccharomyces cerevisiae vector with subsequent purification. T
Prescribed forGlucaGen is used to treat severe hypoglycemic (low blood sugar) reactions which may occur in patients with diabetes mellitus treated with insulin. It is also used as a diagniostic aid. GlucaGen is indicated for use during radiologic examinations to tempor
Chemical NameN.A.
FormulationThe reconstituted solution contains glucagon as hydrochloride 1 mg/mL (1 unit/mL) and lactose monohydrate (107 mg). GlucaGen is supplied at pH 2.5-3.5 and is soluble in water.
Physcial AppearanceSterile, lyophilized white powder
Route of AdministrationSubcutaneous, intramuSubcutaneousular, or Intraven
Recommended DosageInject 1 mL (adults and children, weighing more than 55 lbs (25 kg)) or 0.5 mL (children weighing less than 55 lbs (25 kg)) subcutaneously, intramuscularly, or intravenously. If the weight is not known: children younger than 6 years should be given a 0.5
ContraindicationHypersensitivity
Side EffectsSevere side effects are very rare, although nausea and vomiting may occur occasionally especially with doses above 1 mg or with rapid injection (less than 1 minute). You may also have rapid heart beat for a short while.
Useful Linkhttp://www.novonordisk.co.in/documents/article_page/document/Glucagen.asp
PubMed ID17462598, 17620721, 17623014, 17534934, 15817468
3-D StructureTh1035 (View) or (Download)


Entry 2
(2) Primary information
ID1253
ThPP IDTh1035
Therapeutic Peptide/Protein NameGlucagon recombinant
SequenceHSQGTFTSDYSKYLDSRRAQDFVQWLMNT view full sequnce in fasta
Functional ClassificationIV
Molecular Weight3767.1
Chemical FormulaC165H249N49O51S1
Isoelectric Point9.52
Hydrophobicity-1.197
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionGlucagon is a 29 residue peptide hormone, synthesized in a special non- pathogenic laboratory strain of Escherichia coli bacteria that has been genetically altered by the addition of the gene for glucagons.
Indication/DiseaseUsed to treat severe hypoglycemia, also used in gastrointestinal imaging.
PharmacodynamicsUsed in the treatment of hypoglycemia and in gastric imaging, glucagon increases blood glucose concentration and is used in the treatment of hypoglycemia. Glucagon acts only on liver glycogen, converting it to glucose through the release of insulin. It also relaxes the smooth muscles of the gastrointestinal tract.
Mechanism of ActionGlucagon binds the glucagon receptor(G protein-coupled receptor located in the plasma membrane) which then initiates a dual signaling pathway using both adenylate cyclase activation and increased intracellular calcium. Adenylate cyclase manufactures cAMP (cyclic AMP), which activates protein kinase A (cAMP-dependent protein kinase). This enzyme, in turn, activates phosphorylase kinase, which, in turn, phosphorylates glycogen phosphorylase, converting into the active form called phosphorylase A. Phosphorylase A is the enzyme responsible for the release of glucose-1-phosphate from glycogen polymers. This yields glucose molecules to be released into the blood. Glucagon receptors are found in the liver, kidney, brain and pancreatic islet cells. The glucagon mediated signals lead to an increase in insulin excretion
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of Distribution0.25 L/kg
Clearance13.5  mL/min/kg [Adults with IV 1 mg]
CategoriesHypoglycemic Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationPheochromocytoma
Side EffectsN.A.
Useful Linkhttp://www.drugs.com/pro/glucagen.html
PubMed ID17462598, 17620721, 17623014, 17534934, 15817469
3-D StructureTh1035 (View) or (Download)


Entry 3
(3) Primary information
ID1254
ThPP IDTh1035
Therapeutic Peptide/Protein NameGlucagon recombinant
SequenceHSQGTFTSDYSKYLDSRRAQDFVQWLMNT view full sequnce in fasta
Functional ClassificationIV
Molecular Weight3767.1
Chemical FormulaC165H249N49O51S1
Isoelectric Point9.52
Hydrophobicity-1.197
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionGlucagon is a 29 residue peptide hormone, synthesized in a special non- pathogenic laboratory strain of Escherichia coli bacteria that has been genetically altered by the addition of the gene for glucagons.
Indication/DiseaseUsed to treat severe hypoglycemia, also used in gastrointestinal imaging.
PharmacodynamicsUsed in the treatment of hypoglycemia and in gastric imaging, glucagon increases blood glucose concentration and is used in the treatment of hypoglycemia. Glucagon acts only on liver glycogen, converting it to glucose through the release of insulin. It also relaxes the smooth muscles of the gastrointestinal tract.
Mechanism of ActionGlucagon binds the glucagon receptor(G protein-coupled receptor located in the plasma membrane) which then initiates a dual signaling pathway using both adenylate cyclase activation and increased intracellular calcium. Adenylate cyclase manufactures cAMP (cyclic AMP), which activates protein kinase A (cAMP-dependent protein kinase). This enzyme, in turn, activates phosphorylase kinase, which, in turn, phosphorylates glycogen phosphorylase, converting into the active form called phosphorylase A. Phosphorylase A is the enzyme responsible for the release of glucose-1-phosphate from glycogen polymers. This yields glucose molecules to be released into the blood. Glucagon receptors are found in the liver, kidney, brain and pancreatic islet cells. The glucagon mediated signals lead to an increase in insulin excretion
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of Distribution0.25 L/kg
Clearance13.5  mL/min/kg [Adults with IV 1 mg]
CategoriesHypoglycemic Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationInsulinoma
Side EffectsN.A.
Useful Linkhttp://www.rxlist.com/glucagen-drug.html
PubMed ID17462598, 17620721, 17623014, 17534934, 15817470
3-D StructureTh1035 (View) or (Download)


Entry 4
(4) Primary information
ID1255
ThPP IDTh1035
Therapeutic Peptide/Protein NameGlucagon recombinant
SequenceHSQGTFTSDYSKYLDSRRAQDFVQWLMNT view full sequnce in fasta
Functional ClassificationIV
Molecular Weight3767.1
Chemical FormulaC165H249N49O51S1
Isoelectric Point9.52
Hydrophobicity-1.197
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionGlucagon is a 29 residue peptide hormone, synthesized in a special non- pathogenic laboratory strain of Escherichia coli bacteria that has been genetically altered by the addition of the gene for glucagons.
Indication/DiseaseUsed to treat severe hypoglycemia, also used in gastrointestinal imaging.
PharmacodynamicsUsed in the treatment of hypoglycemia and in gastric imaging, glucagon increases blood glucose concentration and is used in the treatment of hypoglycemia. Glucagon acts only on liver glycogen, converting it to glucose through the release of insulin. It also relaxes the smooth muscles of the gastrointestinal tract.
Mechanism of ActionGlucagon binds the glucagon receptor(G protein-coupled receptor located in the plasma membrane) which then initiates a dual signaling pathway using both adenylate cyclase activation and increased intracellular calcium. Adenylate cyclase manufactures cAMP (cyclic AMP), which activates protein kinase A (cAMP-dependent protein kinase). This enzyme, in turn, activates phosphorylase kinase, which, in turn, phosphorylates glycogen phosphorylase, converting into the active form called phosphorylase A. Phosphorylase A is the enzyme responsible for the release of glucose-1-phosphate from glycogen polymers. This yields glucose molecules to be released into the blood. Glucagon receptors are found in the liver, kidney, brain and pancreatic islet cells. The glucagon mediated signals lead to an increase in insulin excretion
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of Distribution0.25 L/kg
Clearance13.5  mL/min/kg [Adults with IV 1 mg]
CategoriesHypoglycemic Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionWalfarin- Glucagon may increase the anticoagulant effect of warfarin (Coumadin) and other anticoagulants causing an increase in the slow clotting of blood and a greater risk of developing an episode of bleeding.
TargetN.A.
Information of corresponding available drug in the market
Brand NameGlucagon
CompanyEli Lilly
Brand DiscriptionGlucagon, the drug, is a synthetic version of human glucagon and is manufactured by genetic engineering using Escherichia coli.
Prescribed forGlucagon is used to increase the blood glucose level in severe hypoglycemia (low blood glucose). Glucagon is a glucose-elevating drug
Chemical NameN.A.
FormulationGlucagon is available as an emergency kit. The kit contains freeze-dried glucagon as a powder for injection 1 ml syringe of diluent. The powder contains 1 mg (1 unit) of glucagon and 49 mg of lactose. The diluent contains 12 mg/ml of glycerine, water for
Physcial AppearancePowder
Route of AdministrationSubcutaneously or intramuSubcutaneousularly Inject
Recommended DosageAdults and children weighing 44 pounds or more should receive 1mg (1 unit) of glucagon
ContraindicationAllergy
Side EffectsNausea and vomiting may occur occasionally after injection of glucagon, but this may be a symptom of the hypoglycemia for which glucagon is being given. Rare allergic-type reactions may occur with glucagon including itching, respiratory distress, or low blood pressure.
Useful Linkhttp://www.medicinenet.com/glucagon/page2.htm
PubMed ID17462598, 17620721, 17623014, 17534934, 15817471
3-D StructureTh1035 (View) or (Download)


Entry 5
(5) Primary information
ID1256
ThPP IDTh1035
Therapeutic Peptide/Protein NameGlucagon recombinant
SequenceHSQGTFTSDYSKYLDSRRAQDFVQWLMNT view full sequnce in fasta
Functional ClassificationIV
Molecular Weight3767.1
Chemical FormulaC165H249N49O51S1
Isoelectric Point9.52
Hydrophobicity-1.197
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionGlucagon is a 29 residue peptide hormone, synthesized in a special non- pathogenic laboratory strain of Escherichia coli bacteria that has been genetically altered by the addition of the gene for glucagons.
Indication/DiseaseUsed to treat severe hypoglycemia, also used in gastrointestinal imaging.
PharmacodynamicsUsed in the treatment of hypoglycemia and in gastric imaging, glucagon increases blood glucose concentration and is used in the treatment of hypoglycemia. Glucagon acts only on liver glycogen, converting it to glucose through the release of insulin. It also relaxes the smooth muscles of the gastrointestinal tract.
Mechanism of ActionGlucagon binds the glucagon receptor(G protein-coupled receptor located in the plasma membrane) which then initiates a dual signaling pathway using both adenylate cyclase activation and increased intracellular calcium. Adenylate cyclase manufactures cAMP (cyclic AMP), which activates protein kinase A (cAMP-dependent protein kinase). This enzyme, in turn, activates phosphorylase kinase, which, in turn, phosphorylates glycogen phosphorylase, converting into the active form called phosphorylase A. Phosphorylase A is the enzyme responsible for the release of glucose-1-phosphate from glycogen polymers. This yields glucose molecules to be released into the blood. Glucagon receptors are found in the liver, kidney, brain and pancreatic islet cells. The glucagon mediated signals lead to an increase in insulin excretion
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of Distribution0.25 L/kg
Clearance13.5  mL/min/kg [Adults with IV 1 mg]
CategoriesHypoglycemic Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionIndomethacin (Indocin, Indocin-SR) reduces the effect of glucagon.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.novonordisk.co.in/documents/article_page/document/Glucagen.asp
PubMed ID17462598, 17620721, 17623014, 17534934, 15817472
3-D StructureTh1035 (View) or (Download)